Latest news with #Blum
Business Insider
3 days ago
- Business
- Business Insider
Bitget Lists Blum (BLUM) for Spot Trading
Bitget, the leading global cryptocurrency exchange and Web3 company, has announced the listing of Blum (BLUM), a hybrid decentralized exchange based on Telegram. Trading will commence under the BLUM/USDT pair on 27 June 2025, 10:00 (UTC), with withdrawals available on 28 June 2025, 11:00 (UTC). Blum is a decentralized cryptocurrency trading platform that blends the benefits of centralized and decentralized exchanges. It offers a user-friendly trading experience via a Telegram mini-app, supports various crypto assets, and prioritizes user privacy and security. Blum aims to provide efficient, low-cost trading while fostering the Web3 ecosystem. Through off-chain order books and on-chain settlements, BLUM enables efficient trading while preserving self-custody. The platform supports major coins like Bitcoin and Ethereum, as well as meme coins and DeFi tokens, all without the hassle of juggling multiple platforms or wallets. As DeFi evolves to offer more sophisticated tools to users, projects like BLUM demonstrate how hybrid models can simplify access, enhance user experience, and bring self-custody and efficiency to a broader, younger audience. Bitget continues to expand its offerings, positioning itself as a leading platform for cryptocurrency trading. The exchange has established a reputation for innovative solutions that empower users to explore crypto within a secure CeDeFi ecosystem. With an extensive selection of over 800 cryptocurrency pairs and a commitment to broaden its offerings to more than 900 trading pairs, Bitget connects users to various ecosystems, including Bitcoin, Ethereum, Solana, Base, and TON. For more information about Blum (BLUM), visit here. About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform. Bitget is at the forefront of driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency. For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.
Yahoo
4 days ago
- Automotive
- Yahoo
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) on June 12, keeping the price target at $10.00. The analyst cited the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) as one of the factors supporting the optimistic rating, stating that the updated analysis highlights a notable number of patients in remission with no need for further therapy. This is a positive indicator, according to the analyst, especially in comparison to other treatments such as Tecartus. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. While the analyst acknowledged that 38% of responders were still in remission with a median follow-up of 33 months, a slight drop from the 40% reported at 21.5 months, he stated that the results are still impressive. He also cited other promising factors, including the overall survival and event-free survival rates, as well as the absence of new safety concerns. According to Blum, these factors suggest a positive reception from physicians and the potential for higher commercial adoption of obe-cel, supporting the optimistic outlook for Autolus Therapeutics plc (NASDAQ:AUTL). Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, with a focus on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies. While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Hype Malaysia
5 days ago
- Entertainment
- Hype Malaysia
Movie Tea: Punisher To Star In 'Spider-Man: Brand New Day'; Blumhouse Purchases Entire 'Saw' Franchise
Much like when Freddy first duked it out with Jason, the world of cinema is forever changed when two gigantic worlds collide. From the potential meeting of MCU's most brutal anti-hero with our favourite Web-Head, to the union of franchise horror giants, here's the latest news on upcoming movies out of Hollywood. Blumhouse Buys Rights To 'Saw' Series In 25 short years, Blumhouse has become a household name in the world of horror, known for bringing iconic series such as 'Insidious', 'Paranormal Activity', 'Get Out', and more to the public consciousness. It is an absolute juggernaut of the industry, one that recently got bigger thanks to its acquisition of the 'Saw' franchise. Following a lengthy process and undisclosed amounts of money, the torturous mascot, Jigsaw, will now be sharing a seat in the production house's killer doll gallery alongside Megan and Freddy Fazbear… well, at least a portion of it. Blumhouse has specifically purchased the part of the franchise that was previously owned by Oren Koules and Mark Burg. As per Deadline's reporting, Jason Blum, founder of Blumhouse, has now acquired the rights to any and all 'Saw' projects, such as film, TV, games, and even theme park attractions — all of it. Despite this move, Lionsgate still retains partial ownership of the IP and is still on board for any future production and distribution. Blum went on to say that the franchise 'defined a generation of horror' and that 'its cultural impact continues to grow, making this a strategic investment in one of the most recognisable and successful genre properties of the last two decades.' Though it has not been outright stated, many believe that the reason why the franchise was sold off was because of the critical and commercial failure of two of its most recent entries, 2017's 'Jigsaw' and 2020's Chris Rock-led 'Spiral: From The Book Of Saw'. In a brief statement, Koules said that it was 'the right time to pass the baton,' while Burg stated that he wanted to 'move on and tell new stories.' Though the franchise is now under new management, that doesn't mean we are seeing some old and familiar faces. Blum added that James Wan and Leigh Whannell will be brought 'back in the fold' to help guide the future of the franchise. Following this news, Wan went on to say that 'Saw holds a special place in my heart — it's where Leigh and I began our Hollywood journey. Coming back to this world with a fresh perspective is both thrilling and deeply personal. For me, this will mark a significant creative return to the Saw franchise for the first time since the early days, and I'm very much looking forward to embracing the original spirit whilst pushing the legacy forward in bold, unexpected ways.' Jon Bernthal's Punisher Joins Tom Holland In 'Spider-Man: Brand New Day' At last! After months of waiting, we finally got substantive news on everyone's favourite webslinger. Not only do we now have an official release date for the film, but also the news that he's not returning to the big screen alone. Everyone's favourite MCU anti-hero, Frank Castle, is finally making his theatrical debut. This news came to light just prior to the movie's summer shoot in England, but the plot of the film, as well as Bernthal's role in it, remains a mystery. These aren't the only two stars that have been confirmed, as Zendaya and Jacob Batalon are set to reprise their roles as MJ and Ned, respectively. Though we do not know the implications of this team-up in the greater MCU universe, we do know that Bernthal and Holland have a special bond that goes beyond showbiz, as the two have lifted each other up during their respective Marvel roles. Bernthal has been very vocal about his friendship with Holland and has even shared their lives before their MCU roles. For those who remember, the Punisher actor was on 'Jimmy Kimmel Live' when he said, 'We did a film about seven or eight years ago.' The film in question was 2017's 'Pilgrimage'. 'That was where both Tom did his audition for Spider-Man and I did my audition for Punisher. We actually made each other's audition tapes on that film,' Bernthal added. Together, they would help each other out in doing specific scenes or actions that would eventually net them their desired roles. Suffice it to say that it all paid off in the end, and to see them once again share in the fruits of their labour is something we can't wait to see unfold. 'Spider-Man: Brand New Day' is set to hit theatres on 31st July, 2026. Sources: Variety, Empire, Deadline, The Hollywood Reporter What's your Reaction? +1 0 +1 0 +1 0 +1 0 +1 0 +1 0
Business Insider
13-06-2025
- Business
- Business Insider
Analysts' Top Energy Picks: Williams Co (WMB), Kinder Morgan (KMI)
There's a lot to be optimistic about in the Energy sector as 3 analysts just weighed in on Williams Co (WMB – Research Report), Kinder Morgan (KMI – Research Report) and Matador Resources (MTDR – Research Report) with bullish sentiments. Confident Investing Starts Here: Williams Co (WMB) In a report released today, Praneeth Satish from Wells Fargo maintained a Buy rating on Williams Co. The company's shares closed last Friday at $59.73, close to its 52-week high of $61.67. Satish has an average return of 19.2% when recommending Williams Co. According to Satish is ranked #1722 out of 9635 analysts. Currently, the analyst consensus on Williams Co is a Moderate Buy with an average price target of $64.46, a 6.8% upside from current levels. In a report issued on June 4, Bank of America Securities also maintained a Buy rating on the stock with a $67.00 price target. Kinder Morgan (KMI) In a report released today, Michael Blum from Wells Fargo maintained a Buy rating on Kinder Morgan. The company's shares closed last Friday at $27.68. According to Blum is a 5-star analyst with an average return of 10.7% and a 64.8% success rate. Blum covers the NA sector, focusing on stocks such as Excelerate Energy, Inc. Class A, Enterprise Products Partners, and Venture Global, Inc. Class A. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kinder Morgan with a $31.67 average price target, representing a 13.6% upside. In a report issued on June 4, Bank of America Securities also maintained a Buy rating on the stock with a $32.00 price target. Matador Resources (MTDR) In a report released today, Zach Parham from J.P. Morgan maintained a Buy rating on Matador Resources. The company's shares closed last Friday at $50.85. According to Parham is a 4-star analyst with an average return of 8.1% and a 63.9% success rate. Parham covers the NA sector, focusing on stocks such as National Fuel Gas Company, Magnolia Oil & Gas, and Permian Resources. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Matador Resources with a $62.93 average price target, implying a 23.3% upside from current levels. In a report issued on June 6, Siebert Williams Shank & Co also maintained a Buy rating on the stock with a $60.00 price target.
Yahoo
12-06-2025
- Entertainment
- Yahoo
Jason Blum on Those Big Budgets for Horror Movies and Why ‘Sinners' Is the Exception to the Rule
Blumhouse founder Jason Blum has an axe to grind when he hears people say Ryan Coogler's 'Sinners' is not a horror film. Admittedly, the movie is a genre-bending period film and folk fable about the roots of blues music, but it's got vampires killing people in it, so it's a horror movie. And Blum wants you to know it. 'Sinners'' box office success — $350 million worldwide to date — has defied expectations for what an original horror film can do, and even though Blum didn't make it, it's good for his business when the genre as a whole thrives. But much of the discussion around that movie before its release was its hefty budget — a reported $90 million — that complicated its path to profitability. For Blum, he's built his empire on movies made on the cheap that can still be marketed as events, break out in a big way, and spawn franchises. But as Blumhouse has scaled up and the demand for horror has increased, Blumhouse can't make movies as modestly, and the industry too runs into challenges to continue to make horror movies work financially. More from IndieWire 'Titan: The OceanGate Disaster' Review: A Surface-Level Netflix Documentary About the Submersible Implosion Heard Around the World Tom Cruise Has Never Been Happy with His Breath-Defying Underwater Scenes, So 'Final Reckoning' Went Three Times Bigger Blum on Tuesday took the stage in Hollywood at a press event called The Business of Fear, in which he and a panel of Blumhouse and Atomic Monster associates discussed box office trends for the genre and how horror has evolved over the years, such that the genre 'horror' can't be viewed so narrowly. IndieWire asked him about 'Sinners,' a movie he says is 'one of my favorite horror movies I've seen in a long time,' and why he felt 'Sinners' was the rare exception to the rule about making horror movies work on such a massive scale. 'We are definitely not interested in doing movies with that size a budget. That said, I'm glad they had the budget that they had because I think it really helped make the movie rich and incredible and amazing; but we are not going to make horror movies at that level anytime soon, maybe ever,' Blum said in the panel discussion. 'The bigger the budget, the more strain on the creative and the more sanding down of edges. And I think, generally speaking, 'Sinners' being the exception, the product is less interesting. So we are committed to lower budgets to continue to be able to take creative risks and do interesting things, which I think is harder to do when you have more money.' Blumhouse, following its merger with James Wan's Atomic Monster, has scaled up significantly such that it needs to have 'major studio-level success,' as Blum puts it. That means $100 million+ movies, which even for Blum and Wan is rare for movies made for just $1 million. He acknowledges that an indie like last year's 'Longlegs' pulled off the feat, and films like 'Terrifier 3' came dang close, Blum said today 'it's much harder to do what we started doing 15 years ago.' 'So the way that we've addressed that is by adding a bit of money to our model; but still, by studio standards, for instance, the budgets of our movies are 60 percent off the average sticker price, actually probably more, 75 percent off, the average sticker price,' Blum said. Blumhouse has five remaining movies on its slate for 2025, all of them sequels, including 'M3GAN 2.0,' 'Five Night's at Freddy's 2,' a new 'Conjuring' movie, 'The Black Phone 2,' and 'Mortal Kombat 2.' At the event, Blumhouse also announced it's in development on 'Ma 2,' with Octavia Spencer set to return. But it's threading a needle in finding original properties that someday can be the next major franchise for Blumhouse. Together with Atomic Monster it's branching out into video games, an exciting growth area to tell other horror stories, but Blumhouse president Abhijay Prakash explained that they're positioned to adapt one of those games into a film should one break out, though that wasn't the reason it launched the division. Blumhouse also announced at the event it will be adapting another indie horror game hit, 'Phasmaphobia.' Blum is also staying true to the company's philosophy about finding good stories, things that are genuinely scary, rather than trying to stack them with stars or buzzy directors and figure out the rest later. IndieWire asked Blum about a recent viral video from Charli XCX in which she pitched the idea of a 'Final Destination' movie starring all 'It Girls,' and directed by Coralie Fargeat for good measure. Blum hadn't seen the video, but he'd want to hear a bit more. 'Generally, I am not a fan, I think no one on this panel is, of reverse-engineering movies. You never get a good result,' he said. 'It's how, unfortunately, the vast majority of movies are made, but it's very hard to get a good movie reverse-engineering it.' Blum added the studio is unlikely to again release a movie day-and-date in theaters and on Peacock as it did with 'Five Nights at Freddy's' but won't be repeating with the sequel. Horror works best in the theater, not at home, and it's the reason the genre has consistently grown in popularity and still hasn't reached its peak. He says it will lead to movies that are one day constructed very differently for theatrical than they are for streaming — not just a difference in quality or budgets — and horror is very equipped for that evolution. 'Horror, in my mind, is the only genre that you just can't get what you are going to see a horror movie for at home on TV. It doesn't work,' he said. 'The only way to be really scared is when your phone is not with you and when you are in a dark room with a lot of other people and you are fully focused on a movie. You guys try it. Watch a horror movie on streaming, and when you know a scare is coming, look away for two seconds and look back. It stops working. It's just, your suspension of disbelief is broken, and when you are leading that up to a scare, you are just not scared. It's actually made horror in cinema stronger.' Best of IndieWire Guillermo del Toro's Favorite Movies: 56 Films the Director Wants You to See 'Song of the South': 14 Things to Know About Disney's Most Controversial Movie Nicolas Winding Refn's Favorite Films: 37 Movies the Director Wants You to See
